Adrenergic Pharmacology Flashcards
Synthesis of catecholamines
Tyrosine is taken up into the nerve terminal when it is hydroxylated to dihydrocyphenylalanine (DOPA) by tyrosine hydroxylase [note: this is the rate limiting step]. DOPA is decarboxylated to dopamine (DA) by aromatic L-amino acid decarboxylase.
Storage of catecholamines
DA actively transported into vesicle by vesicular monoamine transporter 2 (VMAT2) [promiscuous for all monoamines, susceptible to reserpine]. In the vesicle DA is hydroxylated to NE by dopamine beta-hydroxylase.
In the adrenal medulla NE is further N-methylated to epinephrine by phenylethanolamine-N-methyltransferase (PNMT)
Release of catecholamines
Influx of calcium causes vesicles to fuse with membranes. Guanethidine blocks
Presynaptic regulation of NE release
NE along with cotransmitters, neuropeptide Y and ATP, feedback on prejunctional receptors [alpha2, y2 and p1 respectively] to inhibit transmitter release. NE binding to beta2 results in enhanced neurotransmitter release
Termination of actions of catecholamines
Metabolism of catecholamines does not occur in synaptic cleft. Reuptake and dilution are responsible. [Note: reuptake via NET or DAT is blocked by cocaine, SSRIs, SNRIs and TCAs (imipramine)]
Catecholamine metabolism in nerve terminal
MAO is associated with the mitochondrial surface. Two subgroups: MOA-A preferentially metabolizes NE and 5-HT (serotonin). MAO-B like DA and phenylethylamine best. Both are found in the brain. A is also present in GI, liver, placenta and skin. B is in platelets and lymphocytes. Vanyllylmandelic acid is the major end product, renally excreted, ultra high levels present in pheochromocytoma.
alpha-methyltyrosine
blocks the synthesis of NE by inhibiting TH
methyldopa
inhibits AAADC and forms “false neurotransmitter,” alpha-methylnorepinephrine.
Bretylium and guanethidine
prevent release of NE
Tyramine, ephedrine and amphetamine
rapid, brief NE liberation both by displacing NE in extracellular fluid, and by facilitated exchange diffusion for the outward transport of NE. They also mobilize NE in vesicles by competing for vesicular uptake processes.
Alpha adrenergic receptors
epinephrine > norepinephrine»_space; isoproterenol.
alpha1 has a higher affinity for phenylephrine. Postsynaptic, constricts smooth muscle by Gq activation (PIP3 -> DAG and IP3 -> activation of protein kinase C and release of Ca++ resepectively.)
alpha2 selectively binds clonidine. Presynaptic, feedback inhibition, mediated by Gi and decreased cAMP levels. [Note: tamsulosin selectively treats BPH because it binds only alpha2A which is present in the urinary tract and not alpha2B in the blood vessels]
Beta adrenergic receptors
isoproterenol > epinephrine > norepinephrine.
Beta1 equal affinity for NE and E.
Beta2 higher affinity for E than NE (make it particularly responsive to circulating E)
Beta3 involved in lipolysis, detrussor muscle
All beta receptors are mediated by Gs to increase intracellular cAMP
Blood pressure control mechanisms
Cardiac output - dependent on venous return and heart rate (thus CO is under the control of RAAS and SANS)
Blood volume - dependent on renin-angiotensin-aldosterone system
Peripheral vascular resistance - dependent on RAAS and SANS
Baroreceptor reflex
A drop in blood pressure (as measured by the aortic arch and the carotid sinus) results in SANS firing which causes: increased heart rate, increase ventricular contractility, increase total peripheral resistance, and vascular tone.
An increase in blood pressure results in PANS firing causing a decrease in heart rate.
Reflex can be blocked by ganglion blocking drugs - hexamethonium. Reflex tachycardia can be blocked with beta1 antagonist. Reflex bradycardia can be blocked with muscarinic antagonist
Anti-hypertensive drugs
Can trigger ANS and endocrine feedback loops, resulting in tachycardia and salt and water retention. Beta blockers and diuretics are often part of anti-hypertensive regimens.
sympathomimetic drugs - direct acting agonist
Responses are not reduced by prior treatment with reserpine or guanethidine. Actions of direct-acting amines may actually increase after transmitter depletion because the loss of the endogenous neurotransmitter induces compensatory changes that up-regulate receptors